TYRX Announces First U.S. Implantation of AIGISRx® R Fully Bioresorbable Antibacterial Envelope

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--TYRX, Inc. announced today that the first implantation of its new AIGISRx R Fully Resorbable Antibacterial Envelope has taken place at the Vanderbilt Heart and Vascular Institute in Nashville, TN by Dr. Christopher R. Ellis. The AIGISRx R Antibacterial Envelope received U.S Food and Drug Administration (FDA) clearance on May 20, 2013.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC